Harrow (HROW) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harrow (HROW) has outperformed MannKind (MNKD) over the past year, losing 26.9% versus a loss of 38.9%. Over five years, HROW leads with a +209.6% price change compared with -32.2% for MNKD. Harrow is the larger company by market cap ($1.15 billion vs $1.11 billion), about 1.0 times the size.
On valuation, Harrow trades at a lower forward P/E (11.0x vs 27.1x for MannKind).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | MNKD |
|---|---|---|
| Share price | $30.62 | $3.45 |
| Market cap | $1.15B | $1.11B |
| 1-day change | +0.89% | -7.01% |
| YTD return | -37.51% | -39.15% |
| 1-year return | -26.92% | -38.94% |
| 5-year return | +209.61% | -32.22% |
| Forward P/E | 11.04 | 27.06 |
| EPS (TTM) | $-0.99 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $6.51 |
| 52-week low | $28.54 | $2.23 |
| Distance from 52-week high | -44.18% | -47.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.28% | +127.25% |
| Average volume | 552.72K | 4.46M |
| Shares outstanding | 37.49M | 321.54M |
| Employees | 373 | 591 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HROW has outperformed MNKD by 12.0 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 373 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
HROW vs MNKD FAQ
Which is bigger, Harrow or MannKind?
Harrow (HROW) is larger, with a market capitalization of $1.15B compared with $1.11B for MannKind (MNKD).
Which stock has performed better over the past year, HROW or MNKD?
HROW returned -26.92% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and MannKind in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Harrow and Biotechnology for MannKind.